Category - Amgen

• Amgen taps research firm to reassess Tavneos data
• Amgen taps research firm to reassess Tavneos data
• Amgen taps research firm to reassess Tavneos data
• Popular GLP-1 weight-loss drugs may be getting better
• Amgen Stock: Is AMGN Outperform­ing the Healthcare Sector?
• Amgen Stock: Is AMGN Outperform­ing the Healthcare Sector?
• Why Wall Street Thinks This Dividend Stock Could Jump 30%
• Why Wall Street Thinks This Dividend Stock Could Jump 30%
• What to Expect From Amgen's Next Quarterly Earnings Report
• Valley bio students mimic experiment­s done at Amgen
• Amgen to build new research facility
• Obesity drug tum trouble
• Amgen announces $900M expansion in New Albany
• Not-So-Bad Clinical Trial Results
• Not-So-Bad Clinical Trial Results
• An inside look at Amgen’s fall
• Firm reports success of weight loss drug
• Firm reports success of weight loss drug
• Amgen to test obesity drug for treating liver, kidney diseases
• Lung cancer drug secures approval
• Pharma giant Amgen opens manufactur­ing facility in Ohio
• Pharma giant Amgen opens manufactur­ing facility in Ohio
• Pharma giant Amgen opens manufactur­ing facility in Ohio
• Weight loss drug results hopeful
• Amgen cuts Horizon Therapeuti­cs jobs
• Feds, Amgen reach deal on $28B pharma merger
• FTC, Amgen settle to allow $28b merger
• FTC pause on Amgen
• Amgen’s $27.8b Horizon acquisitio­n blocked